Hai cercato la traduzione di preparations da Greco a Inglese

στην αγγλική γλώσσα for production of food preparations of cn code 19011000
in english for production of food preparations of cn code 19011000

recording of core data for herbal drugs/ herbal drug preparations (*)
points to consider on good agricultural and collection practice for starting materials of herbal origin (*)

annex 3 – table: state of practical preparations (june 2006)
annex 3 - table: state of practical preparations (june 2006)

στην αγγλική γλώσσα broken rice of cn code 10064000 for production of food preparations of cn code 19011000
in english broken rice of cn code 10064000 for production of food preparations of cn code 19011000

test procedures and acceptance criteria for herbal drugs, herbal drug preparations and herbal medicinal products
test procedures and acceptance criteria for herbal drugs, herbal drug preparations and herbal medicinal products

concept paper on the development of an appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia
concept paper on the development of an appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia

adjustment for baseline covariates points to consider on the clinical investigation of medicinal products in the treatment of asthma note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence in women note for guidance on the evaluation of medicinal products for treatment of migraine appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia note for guidance on the evaluation of medicinal products indicated for thrombolysis in acute myocardial infarction addendum on acute cardiac failure to the cpmp note for guidance on clinical investigation of medicinal products in the treatment of acute cardiac failure note for guidance on the evaluation of medicinal products for the treatment of dyslipoproteinaemia points to consider on clinical investigation of slow- acting anti- rheumatic medicinal products in rheumatoid arthritis points to consider on irritable bowel syndrome points to consider document on the evaluation of new anti- fungal agents for invasive fungal infections points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications:
adjustment for baseline covariates points to consider on the clinical investigation of medicinal products in the treatment of asthma note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence in women note for guidance on the evaluation of medicinal products for treatment of migraine appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia note for guidance on the evaluation of medicinal products indicated for thrombolysis in acute myocardial infarction addendum on acute cardiac failure to the cpmp note for guidance on clinical investigation of medicinal products in the treatment of acute cardiac failure note for guidance on the evaluation of medicinal products for the treatment of dyslipoproteinaemia points to consider on clinical investigation of slow-acting anti-rheumatic medicinal products in rheumatoid arthritis points to consider on irritable bowel syndrome points to consider document on the evaluation of new anti-fungal agents for invasive fungal infections points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications: